Merrill Lynch Resumes Coverage on Genzyme (GENZ) with a Buy
More News related to GENZ
- Genzyme Seeks U.S. Approval for Clolar(R) to Treat Adult AML
- Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases
- Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- Four Join Board of SAFE-BioPharma Association
More News related to New Coverage
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Merrill Lynch resumes coverage on Genzyme (Nasdaq: GENZ) with a Buy.
Genzyme Corporation is a biotechnology company. The Company operates in six units.
Related Categories
New CoverageStocks Mentioned
+2.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
